Oxcarbazepine (All indications)

Cognitive developmental disorders/delay (> 6 years old)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S12731
R53721		 Bjørk (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2022 Diagnosis of intellectual disability (ID): mild ID (F70), moderate ID (F71), severe ID (F72), and profound ID (F73) (between 6.1 and 7.9 years old) during pregnancy (anytime or not specified) population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 2.53 [1.32;4.86] C
excluded (control group) 		16/1,539   21/5,073 37 1,539
ref
S12733
R53722		 Bjørk (Oxcarbazepine) (Controls unexposed NOS), 2022 Diagnosis of intellectual disability (ID): mild ID (F70), moderate ID (F71), severe ID (F72), and profound ID (F73) (between 6.1 and 7.9 years old) during pregnancy (anytime or not specified) population based cohort retrospective unexposed (general population or NOS) excluded Adjustment: Yes 1.95 [1.19;3.18]
excluded (control group) 		16/1,539   16,384/4,463,879 16,400 1,539
ref
S12732
R53723		 Bjørk (Oxcarbazepine) (Controls unexposed, sick), 2022 Diagnosis of intellectual disability (ID): mild ID (F70), moderate ID (F71), severe ID (F72), and profound ID (F73) (between 6.1 and 7.9 years old) during pregnancy (anytime or not specified) population based cohort retrospective unexposed, sick Adjustment: Yes 0.87 [0.48;1.58] -/1,429   139/21,634 130 1,429
ref
Total 1 studies 0.87 [0.48;1.58] 130 1,429
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Bjørk (Oxcarbazepine) (Controls unexposed, sick), 2022Bjørk, 2022 1 0.87[0.48; 1.58]1301,4290%ROB confusion: seriousROB selection: lowROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate0.22.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Oxcarbazepine) (Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.87[0.48; 1.58]1301,429 -NABjørk (Oxcarbazepine) (Controls unexposed, sick), 2022 1 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 0.87[0.48; 1.58]1301,429 -NABjørk (Oxcarbazepine) (Controls unexposed, sick), 2022 1 Tags Adjustment   - Yes  - Yes 0.87[0.48; 1.58]1301,429 -NABjørk (Oxcarbazepine) (Controls unexposed, sick), 2022 1 All studiesAll studies 0.87[0.48; 1.58]1301,429 -NABjørk (Oxcarbazepine) (Controls unexposed, sick), 2022 10.210.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 12731, 12733

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.95[1.19; 3.19]16,4001,539 -NABjørk (Oxcarbazepine) (Controls unexposed NOS), 2022 1 unexposed, sick controlsunexposed, sick controls 0.87[0.48; 1.58]1301,429 -NABjørk (Oxcarbazepine) (Controls unexposed, sick), 2022 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 2.53[1.32; 4.86]371,539 -NABjørk (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2022 10.510.01.0